HIV inhibiting pyrimidines derivatives

Details HIV inhibiting pyrimidines derivatives HIV inhibiting pyrimidines derivatives

2006-10-24

2006-10-24

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S247000, C544S297000

Reexamination Certificate

active

07125879

ABSTRACT:
This invention concerns HIV replication inhibitors of formula (I) the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing −a1=a2−a3=a4—and −b1=b2−b3=b4represents pheynl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl, substituted C1-6alkyl, C1-6alkylcarbonyl; R2is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH?2?, —NHC(═O)R6, —C(═NH)R6or a 5-membered hetrocycl; X1is —NR5—, —NH—NH—, —N═N—, —O—, —C(═O)—, C1-4alkanediyl, —CHOH—, —S—, —S(═O)p—, —X2—C1-4alkanediyl- or —C1-4alkanediyl-X2—; R3is NHR13, NR13R14; —C(═O)—NHR13; —C(═O)—NR13R14; —C(═O)—R15; —CH═N—NH—C(═O)—R16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl; substituted C2-6alkynyl; substituted C2-6alkylenyl; C1-6alkyl substituted with hydroxy and a second substituent; —C(═N—O—R8)—C1-4alkyl; R7; or —X3—R7; R4is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl) amino; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them

REFERENCES:
patent: 5958935 (1999-09-01), Davis et al.
patent: 6838464 (2005-01-01), Pease et al.
patent: 0945443 (1999-09-01), None
patent: 1002795 (2000-05-01), None
patent: WO 9950250 (1999-10-01), None
patent: WO 0027825 (2000-05-01), None
patent: WO 03/016306 (2003-02-01), None
International Search Report dated Feb. 7, 2005 for International Application No. PCT/EP2004/052028 (related by subject matter).
Pavia, Andrew T., “Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine”, Internet Article, 'Online!, Jul. 9, 2002, XP002274550.
Young, Benjamin, “Can Abacavir Be Given Once-a-Day?”, Internet Article, 'Online!, Sep. 16, 2003, XP002274551.
Gilead Sciences Inc., “Gilead initiates study 934, a 48-week clinical trial evaluating Viread™ and Emtriva™ versus Combivir™”, Internet Article, 'Online!, August 11, 2003, XP002314669.
Squires, Kathleen E., “An introduction to nucleoside and nucleotide analogues”, Antirviral therapy, vol. 6, suppl. 3, pp. 1-14 (2001) (XP009042950).
D'Auria et al., “Photochemical dimerization in solution of arylacrylonitrile derivatives,” Tetrahedron Elsevier Science Publishers, Amsterdam, NL, vol. 53, No. 51, pp. 17307-17316 (Dec. 22, 1997) (p. 17311; Compound No. 7) (XP004106551; ISSN: 0040-4020).
International Search Report dated Nov. 26, 2002 for corresponding European Patent Application No. PCT/EP02/08953 (WO2003016306).

Affiliated with

Also associated with

Rating

HIV inhibiting pyrimidines derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV inhibiting pyrimidines derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV inhibiting pyrimidines derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3708835